CESAR Director Dr. Eric Wish Talks About Synthetic Cannabinoids in DC on the Kojo NNamadi Show
The July 23rd Kojo Nnamadi Show segment, Synthetic Cannabinoids and Public Health, featured CESAR Director, Dr. Eric Wish, Washington Post reporter Peter Hermann, the Director of the Community for Creative Nonviolence, Donald Page, and the Director of the D.C. Department of Public Health, Dr. LaQuandra Nesbitt. The show is available online at https://thekojonnamdishow.org/shows/2015-07-23/synthetic-marijuana-in-d-c.
Washington Post Article: "The Scariest Thing About Synthetic Drugs Is Everything That's Unknown"
CESAR Director Dr. Eric Wish is quoted in the July 18th Washington Post article, "The Scariest Thing About Synthetic Drugs Is Everything That's Unknown," discussing synthetic drugs.
CESAR Director Dr. Eric Wish Interviewed About Synthetic Cannabinoids
CESAR Director Dr. Eric Wish was recently interviewed by Al Jazeera America about synthetic cannabinoids. According to Dr. Wish, "When someone takes this drug, they are literally playing Russian Roulette. They do not know what's in it and they do not know how it's going to affect them. It may have been fine with a different batch or with a different friend, but it may all change when they take it." The interview can be viewed online at http://go.umd.edu/WishAJAM. In June, Dr. Wish talked with WAMU on why DC is cracking down on stores selling synthetic drugs (http://go.umd.edu/WishWAMU).
Second CDEWS Study Finds Synthetic Cannabinoids in Adults and Juveniles in Washington, DC, Denver, and Tampa Criminal Justice Populations
The Community Drug Early Warning System (CDEWS) provides information about emerging drug use in local communities by sampling anonymous urine specimens that were previously collected by a criminal justice agency, tested for a limited panel of drugs, and are ready to be discarded. CDEWS re-tests the specimens for an expanded panel of more than 75 drugs. The second CDEWS study found that the types of SC metabolites detected vary considerably by site and that DC juveniles may be using different formulations of SC than DC adults. Implications for law enforcement and public health are also discussed in the report. For more information, see the CDEWS-2 report or the CESAR FAX issue highlighting the report. The first CDEWS report, published in 2013, can be found here.
CESAR FAX Special Series on Synthetic Cannabinoids Updated
Stay on top of the most recent research and survey results regarding synthetic cannabinoids with this updated compilation of CESAR FAX issues on the topic.
CESAR FAX Special Series on Buprenorphine Updated
While research indicates that buprenorphine is an effective drug for treating opioid dependence, we feel that the potential for its nonmedical use and related unintended consequences may be going unnoticed. This series of publications on buprenorphine was designed to highlight several indicators of the increased availability, diversion, and misuse of buprenorphine.
CESAR Awarded Five-Year NIDA Funding to Develop the National Drug Early Warning System (NDEWS)
The National Drug Early Warning System (NDEWS) will monitor emerging trends to enable health experts to respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased use of designer synthetic compounds. For more information, see this special edition of the CESAR FAX, or go to the NIDA Press Release.
Maryland's Successful Community Services Locator Is Now Available for Other Jurisdictions
CESAR would like to work with you to implement a Community Services Locator (CSL) or a secure Inmate Community Services Locator (ICSL) in your area. For more information, see our CSL and ICSL brochures. Check out the Maryland Community Services Locator (MDCSL; www.mdcsl.org) to see a working example of this invaluable tool.
CESAR Article Warning of Emerging Epidemic of Buprenorphine Misuse Published in Journal of Addictive Diseases
The article, "The Emerging Buprenorphine Epidemic in the United States," was recently published in the Journal of Addictive Diseases. The authors sampled for expanded drug testing of 1,061 urine specimens collected by Maryland Division of Parole and Probation staff. They found an increase in the percentage of individuals testing positive for buprenorphine and found that these specimens often contained other drugs, suggesting misuse. Subsequent interviews with 15 probationers and parolees in Baltimore, Maryland, showed wide-scale availability of buprenorphine on the street and in prisons. Medical examiners and drug testing programs should immediately initiate routine testing for buprenorphine to track a possible outbreak of buprenorphine diversion and misuse. Physician education programs should redouble their efforts to teach strategies to deter diversion and misuse of the drug.
CESAR FAX Special Series on Buprenorphine Updated
While research indicates that buprenorphine is an effective drug for treating
opioid dependence, we feel that the potential for its nonmedical use and related
unintended consequences may be going unnoticed. This
publications on buprenorphine was designed to highlight several indicators
of the increased availability, diversion, and misuse of buprenorphine.